Characterization of antibiotic-resistance traits in Akkermansia muciniphila strains of human origin

Filardi, Rossella; Gargari, Giorgio; Mora, Diego; Arioli, Stefania

doi:10.1038/s41598-022-23980-6

“…Specifically, a total of 538 and 204 hits were generated among B. fragilis sensu stricto (n=275) and B. fragilis A (n=102) genomes, respectively, for the presence of adeF that confers resistance to fluoroquinolone and tetracycline antibiotics by acting as an efflux pump component [74]. This AMR gene has been detected previously among Bacteroides clinical isolates as well as being prevalent among other gut-associated bacteria including Akkermansia muciniphila and the pathogen Acinetobacter baumannii [75][76][77][78]. Tetracycline resistance gene variants were also detected among B. fragilis sensu stricto and B. fragilis A genomes, including tetB, tetC, tetM, tetQ and tetX.…”

Section: Amr Genes Encoded In B Fragilis Genomesmentioning

confidence: 99%

Genomic analyses of Bacteroides fragilis: subdivisions I and II represent distinct species

English,

Newberry,

Hoyles

et al. 2023

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Bacteroides fragilis is a Gram-negative anaerobe that is a member of the human gastrointestinal microbiota and is frequently found as an extra-intestinal opportunistic pathogen. B. fragilis comprises two distinct groups – divisions I and II – characterized by the presence/absence of genes [cepA and ccrA (cfiA), respectively] that confer resistance to β-lactam antibiotics by either serine or metallo-β-lactamase production. No large-scale analyses of publicly available B. fragilis sequence data have been undertaken, and the resistome of the species remains poorly defined. Hypothesis/Gap Statement. Reclassification of divisions I and II B. fragilis as two distinct species has been proposed but additional evidence is required. Aims. To investigate the genomic diversity of GenBank B. fragilis genomes and establish the prevalence of division I and II strains among publicly available B. fragilis genomes, and to generate further evidence to demonstrate that B. fragilis division I and II strains represent distinct genomospecies. Methodology. High-quality (n=377) genomes listed as B. fragilis in GenBank were included in pangenome and functional analyses. Genome data were also subject to resistome profiling using The Comprehensive Antibiotic Resistance Database. Results. Average nucleotide identity and phylogenetic analyses showed B. fragilis divisions I and II represent distinct species: B. fragilis sensu stricto (n=275 genomes) and B. fragilis A (n=102 genomes; Genome Taxonomy Database designation), respectively. Exploration of the pangenome of B. fragilis sensu stricto and B. fragilis A revealed separation of the two species at the core and accessory gene levels. Conclusion. The findings indicate that B. fragilis A, previously referred to as division II B. fragilis , is an individual species and distinct from B. fragilis sensu stricto. The B. fragilis pangenome analysis supported previous genomic, phylogenetic and resistome screening analyses collectively reinforcing that divisions I and II are two separate species. In addition, it was confirmed that differences in the accessory genes of B. fragilis divisions I and II are primarily associated with carbohydrate metabolism and suggest that differences other than antimicrobial resistance could also be used to distinguish between these two species.

show abstract

“…Based on the antibiotic susceptibility evaluation tests, it was found that AKK PROBIO was indeed resistant to moxifloxacin. All A. muciniphila strains, including the type strain, showed low sensitivity to ciprofloxacin [44]. Both moxifloxacin and ciprofloxacin are quinolone antibiotics, so A. muciniphila may be innately resistant to quinolone antibiotics.…”

Section: Discussionmentioning

confidence: 99%

“…The prediction yielded only three resistance genes belonging to two categories, indicating that AKK PROBIO is susceptible to the majority of antibiotics. According to the study by Filardi et al, all strains of A. muciniphila harbor the gene adeF, encoding for a subunit of the resistance-nodulation-cell division efflux pump system [44].…”

Section: Discussionmentioning

confidence: 99%

Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO

Ma,

Tian,

Yu

et al. 2024

Foods

3

0

View full text Add to dashboard Cite

In addition to providing certain health advantages to the host, a bacterial strain must possess a clearly defined safety profile to be regarded as a probiotic. In this study, we present a thorough and methodical assessment of the safety of a novel strain of bacteria, Akkermansia muciniphila PROBIO, which was isolated from human feces. Firstly, we examined the strain’s overall features, such as its gastrointestinal tolerance and its physiological and biochemical traits. Next, we verified its genotoxic properties through bacterial reverse mutation and in vitro mammalian cell micronucleus assays. The drug sensitivity of A. muciniphila PROBIO was subsequently examined through an analysis of its antibiotic resistance genes. Additionally, the toxicological impact was verified through acute and sub-chronic toxicity studies. A genome-based safety assessment was conducted to gain further insights into gene function, including potential virulence factors and pathogenic properties. Finally, we assessed whether moxifloxacin resistance in A. muciniphila PROBIO is transferred using in vitro conjugation experiments. A. muciniphila PROBIO exhibited superior gastrointestinal tolerance, with no observed hematological or histopathological abnormalities. Moreover, the outcomes pertaining to mutagenic, clastogenic, or toxic impacts were found to be negative, even at exceedingly high dosages. Moreover, no adverse effects associated with the test substance were observed during the examination of acute and sub-chronic toxicity. Consequently, it was plausible to estimate the no-observed-adverse-effect level (NOAEL) to be 6.4 × 1011 viable bacteria for an average individual weighing 70 kg. Additionally, only three potential drug resistance genes and one virulence factor gene were annotated. A. muciniphila PROBIO is naturally resistant to moxifloxacin, and resistance does not transfer. Collectively, the data presented herein substantiate the presumed safety of A. muciniphila PROBIO for its application in food.

show abstract

“…The total cell count and viability of the bacterial cultures were assessed by flow cytometry, following the ISO 10932 procedure [ 40 ], with some modifications as previously reported [ 41 ]. Bacterial cultures were grown at 30 °C for 24 h in ISO-Sensitest broth (Oxoid) supplemented with 10% v / v MRS (Oxoid) and diluted in filtered phosphate-buffered saline (PBS, pH = 7.4) to achieve a concentration of approximately 1.0 × 10 6 cells/mL.…”

Section: Methodsmentioning

confidence: 99%

Biotechnological Potential and Safety Evaluation of Dextran- and Riboflavin-Producing Weisella cibaria Strains for Gluten-Free Baking

Russo,

Diez-Ozaeta,

Mangieri

et al. 2023

Foods

1

0

View full text Add to dashboard Cite

Gluten consumption causes several immunological and non-immunological intolerances in susceptible individuals. In this study, the dextran-producing Weissella cibaria BAL3C-5 and its derivative, the riboflavin-overproducing strain BAL3C-5 C120T, together with a commercial bakery yeast, were used to ferment gluten-free (GF)-doughs obtained from corn and rice flours at two different concentrations and supplemented with either quinoa, buckwheat, or chickpea to obtain laboratory-scale GF bread. The levels of dextran, riboflavin, and total flavins were determined in the fermented and breads. Both strains grew in fermented doughs and contributed dextran, especially to those made with corn plus quinoa (~1 g/100 g). The highest riboflavin (350–150 µg/100 g) and total flavin (2.3–1.75 mg/100 g) levels were observed with BAL3C-5 C120T, though some differences were detected between the various doughs or breads, suggesting an impact of the type of flour used. The safety assessment confirmed the lack of pathogenic factors in the bacterial strains, such as hemolysin and gelatinase activity, as well as the genetic determinants for biogenic amine production. Some intrinsic resistance to antibiotics, including vancomycin and kanamycin, was found. These results indicated the microbiological safety of both W. cibaria strains and indicated their potential application in baking to produce GF bread.

show abstract

Characterization of antibiotic-resistance traits in Akkermansia muciniphila strains of human origin

Cited by 12 publications

References 58 publications

Genomic analyses of Bacteroides fragilis: subdivisions I and II represent distinct species

Genomic analyses of Bacteroides fragilis: subdivisions I and II represent distinct species

Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO

Biotechnological Potential and Safety Evaluation of Dextran- and Riboflavin-Producing Weisella cibaria Strains for Gluten-Free Baking

Contact Info

Product

Resources

About